NSRX
Nasus Pharma Ltd.
Price Chart
Latest Quote
$3.30
+0.18 (+5.77%)
Current Price
| Previous Close | $3.12 |
| Open | $3.11 |
| Day High | $3.38 |
| Day Low | $3.04 |
| Volume | 34,249 |
Stock Information
| Shares Outstanding | 11.71M |
| Total Debt | $118K |
| Cash Equivalents | $4.29M |
| Net Income | $-5.80M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $38.65M |
| EPS (TTM) | $-0.72 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $32.37M |
| Income | $-5.80M |
| Book/sh | $0.31 |
| Cash/sh | $0.37 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 1.98 |
| Current Ratio | 2.25 |
| Debt/Eq | 4.26 |
Returns & Margins
| ROA | -107.15% |
Ownership
| Insider Ownership | 49.11% |
| Institutional Ownership | 18.57% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 10.75 |
Analyst Data
| Recommendation | buy |
| Target Price | $19.67 |
Technical Indicators
| SMA20 | $3.10 |
| SMA50 | $2.97 |
| SMA200 | $5.46 |
| RSI | 51.11 |
| ATR | 0.2550 |
| Shares Float | 4.86M |
| Short Float | 2.63% |
| Short Ratio | 2.53 |
| Rel Volume | 0.72 |
Performance History
| Week | +4.76% |
| Month | +14.98% |
| Quarter | +32.00% |
| 6 Months | -48.19% |
| YTD | -56.29% |
| 10 Years | -60.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $3.30 | 34,249 |
| 2026-06-22 | $3.12 | 17,400 |
| 2026-06-18 | $3.07 | 15,600 |
| 2026-06-17 | $3.08 | 21,100 |
| 2026-06-16 | $3.07 | 36,200 |
| 2026-06-15 | $3.15 | 59,100 |
| 2026-06-12 | $2.88 | 42,200 |
| 2026-06-11 | $3.17 | 27,700 |
| 2026-06-10 | $3.03 | 60,000 |
| 2026-06-09 | $2.90 | 14,700 |
| 2026-06-08 | $2.91 | 33,300 |
| 2026-06-05 | $2.93 | 30,700 |
| 2026-06-04 | $3.24 | 60,700 |
| 2026-06-03 | $3.10 | 16,500 |
| 2026-06-02 | $3.26 | 47,700 |
| 2026-06-01 | $3.34 | 79,000 |
| 2026-05-29 | $3.36 | 290,100 |
| 2026-05-28 | $3.20 | 35,600 |
| 2026-05-27 | $3.02 | 21,100 |
| 2026-05-26 | $2.83 | 13,400 |
About Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
đ° Latest News
No news articles available at the moment. Check back later for updates on NSRX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $4,904,000 | $1,078,000 | $1,147,000 | $2,042,000 |
| Other Income Expense | $-979,000 | $-445,000 | $191,000 | $-92,000 |
| Other Non Operating Income Expenses | $-27,000 | $-2,000 | $-28,000 | $-4,000 |
| Net Non Operating Interest Income Expense | $78,000 | $-29,000 | $-49,000 | $-18,000 |
| Total Other Finance Cost | $-78,000 | $29,000 | $49,000 | - |
| Operating Expense | $4,904,000 | $1,078,000 | $1,147,000 | $2,042,000 |
| General And Administrative Expense | $2,667,000 | $743,000 | $580,000 | $926,000 |
| Interest Expense | - | $29,000 | $49,000 | $18,000 |
| Interest Expense Non Operating | - | $29,000 | $49,000 | $18,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-5,805,000 | $-1,552,000 | $-1,005,000 | $-2,152,000 |
| Net Interest Income | $78,000 | $-29,000 | $-49,000 | $-18,000 |
| Normalized Income | $-4,853,000 | $-1,109,000 | $-1,224,000 | $-2,064,000 |
| Net Income From Continuing And Discontinued Operation | $-5,856,000 | $-1,532,000 | $-1,051,000 | $-1,711,000 |
| Total Operating Income As Reported | $-4,904,000 | $-1,078,000 | $-1,147,000 | $-2,042,000 |
| Net Income Common Stockholders | $-5,856,000 | $-1,532,000 | $-1,051,000 | $-1,711,000 |
| Net Income | $-5,856,000 | $-1,532,000 | $-1,051,000 | $-1,711,000 |
| Net Income Including Noncontrolling Interests | $-5,856,000 | $-1,532,000 | $-1,051,000 | $-1,711,000 |
| Net Income Discontinuous Operations | $-51,000 | $20,000 | $-46,000 | $441,000 |
| Net Income Continuous Operations | $-5,805,000 | $-1,552,000 | $-1,005,000 | $-2,152,000 |
| Pretax Income | $-5,805,000 | $-1,552,000 | $-1,005,000 | $-2,152,000 |
| Operating Income | $-4,904,000 | $-1,078,000 | $-1,147,000 | $-2,042,000 |
| Per Share | ||||
| Diluted EPS | $-0.72 | $-0.22 | $-0.20 | $-0.24 |
| Basic EPS | $-0.72 | $-0.22 | $-0.15 | $-0.24 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,952,000 | $-635,000 | $-1,366,000 | $-2,046,000 |
| Total Unusual Items | $-952,000 | $-443,000 | $219,000 | $-88,000 |
| Total Unusual Items Excluding Goodwill | $-952,000 | $-443,000 | $219,000 | $-88,000 |
| EBITDA (Bullshit earnings) | $-4,904,000 | $-1,078,000 | $-1,147,000 | $-2,134,000 |
| EBIT | $-4,904,000 | $-1,078,000 | $-1,147,000 | $-2,134,000 |
| Diluted Average Shares | $8,010,126 | $7,027,725 | $7,057,820 | $7,027,725 |
| Basic Average Shares | $8,010,126 | $7,027,725 | $6,889,708 | $7,027,725 |
| Diluted NI Availto Com Stockholders | $-5,856,000 | $-1,532,000 | $-1,051,000 | $-1,711,000 |
| Gain On Sale Of Security | $-952,000 | $-443,000 | $219,000 | $-88,000 |
| Research And Development | $2,237,000 | $335,000 | $567,000 | $1,116,000 |
| Selling General And Administration | $2,667,000 | $743,000 | $580,000 | $926,000 |
| Other Gand A | $2,667,000 | $743,000 | $580,000 | $926,000 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,768,000 | $-3,212,000 | $-3,797,000 | $-2,785,000 |
| Total Assets | $5,004,000 | $717,000 | $444,000 | $417,000 |
| Total Non Current Assets | $149,000 | $260,000 | $0 | $0 |
| Non Current Deferred Assets | $0 | $260,000 | $0 | - |
| Current Assets | $4,855,000 | $457,000 | $444,000 | $417,000 |
| Other Current Assets | $186,000 | $29,000 | $234,000 | $246,000 |
| Restricted Cash | $54,000 | $27,000 | $17,000 | $17,000 |
| Prepaid Assets | $329,000 | $117,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $4,286,000 | $284,000 | $193,000 | $154,000 |
| Cash And Cash Equivalents | $1,237,000 | $284,000 | $193,000 | $154,000 |
| Debt | ||||
| Total Debt | $118,000 | $1,802,000 | $2,457,000 | $1,572,000 |
| Long Term Debt And Capital Lease Obligation | $73,000 | $0 | - | - |
| Current Debt And Capital Lease Obligation | $45,000 | $1,802,000 | $2,457,000 | $1,572,000 |
| Net Debt | - | $1,518,000 | $2,264,000 | $1,418,000 |
| Current Debt | - | $1,802,000 | $2,457,000 | $1,572,000 |
| Other Current Borrowings | - | $1,802,000 | $2,457,000 | $1,572,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,236,000 | $3,929,000 | $4,241,000 | $3,202,000 |
| Total Non Current Liabilities Net Minority Interest | $73,000 | $0 | $0 | $0 |
| Current Liabilities | $2,163,000 | $3,929,000 | $4,241,000 | $3,202,000 |
| Other Current Liabilities | $503,000 | $597,000 | $513,000 | $514,000 |
| Payables And Accrued Expenses | $1,382,000 | $1,495,000 | $1,271,000 | $1,116,000 |
| Payables | $829,000 | $651,000 | $655,000 | $771,000 |
| Accounts Payable | $829,000 | $651,000 | $655,000 | $771,000 |
| Equity | ||||
| Common Stock Equity | $2,768,000 | $-3,212,000 | $-3,797,000 | $-2,785,000 |
| Total Equity Gross Minority Interest | $2,768,000 | $-3,212,000 | $-3,797,000 | $-2,785,000 |
| Stockholders Equity | $2,768,000 | $-3,212,000 | $-3,797,000 | $-2,785,000 |
| Retained Earnings | $-18,520,000 | $-12,664,000 | $-11,132,000 | $-10,081,000 |
| Other | ||||
| Ordinary Shares Number | $9,015,383 | $9,059,634 | $9,059,634 | $9,059,634 |
| Share Issued | $9,015,383 | $9,059,634 | $9,059,634 | $9,059,634 |
| Tangible Book Value | $2,768,000 | $-3,212,000 | $-3,797,000 | $-2,785,000 |
| Invested Capital | $2,768,000 | $-1,410,000 | $-1,340,000 | $-1,213,000 |
| Working Capital | $2,692,000 | $-3,472,000 | $-3,797,000 | $-2,785,000 |
| Capital Lease Obligations | $118,000 | $0 | - | - |
| Total Capitalization | $2,768,000 | $-3,212,000 | $-3,797,000 | $-2,785,000 |
| Additional Paid In Capital | $21,288,000 | $9,432,000 | $7,316,000 | $7,292,000 |
| Capital Stock | $0 | $20,000 | $19,000 | $4,000 |
| Common Stock | $0 | $20,000 | $19,000 | $4,000 |
| Long Term Capital Lease Obligation | $73,000 | $0 | - | - |
| Current Capital Lease Obligation | $45,000 | $0 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | $233,000 | $35,000 | - | - |
| Current Accrued Expenses | $553,000 | $844,000 | $616,000 | $345,000 |
| Net PPE | $149,000 | $0 | - | - |
| Gross PPE | $149,000 | $0 | - | - |
| Other Properties | $149,000 | - | - | - |
| Other Short Term Investments | $3,049,000 | $0 | - | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,932,000 | $-665,000 | $-1,029,000 | $-1,211,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,918,000 | $-665,000 | $-1,029,000 | $-1,211,000 |
| Cash From Discontinued Operating Activities | $-56,000 | $-4,000 | $-47,000 | $325,000 |
| Cash Flow From Continuing Operating Activities | $-4,862,000 | $-661,000 | $-982,000 | $-1,536,000 |
| Operating Gains Losses | $960,000 | $447,000 | $-232,000 | $98,000 |
| Investing Activities | ||||
| Capital Expenditure | $-14,000 | - | - | - |
| Investing Cash Flow | $-3,014,000 | $0 | $0 | $-160,000 |
| Cash From Discontinued Investing Activities | $0 | $0 | $0 | $-160,000 |
| Cash Flow From Continuing Investing Activities | $-3,014,000 | $0 | $0 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $8,485,000 | $0 | $0 | - |
| Financing Cash Flow | $8,920,000 | $770,000 | $1,055,000 | $1,238,000 |
| Cash From Discontinued Financing Activities | $0 | $0 | $0 | $-231,000 |
| Cash Flow From Continuing Financing Activities | $8,920,000 | $770,000 | $1,055,000 | $1,469,000 |
| Net Common Stock Issuance | $8,485,000 | $0 | $0 | - |
| Common Stock Issuance | $8,485,000 | $0 | $0 | - |
| Net Other Financing Charges | - | $-230,000 | - | - |
| Other | ||||
| Issuance Of Debt | $435,000 | $1,000,000 | $1,055,000 | $1,466,000 |
| End Cash Position | $1,291,000 | $311,000 | $210,000 | $171,000 |
| Beginning Cash Position | $311,000 | $210,000 | $171,000 | $314,000 |
| Effect Of Exchange Rate Changes | $-8,000 | $-4,000 | $13,000 | $-10,000 |
| Changes In Cash | $988,000 | $105,000 | $26,000 | $-133,000 |
| Net Issuance Payments Of Debt | $435,000 | $1,000,000 | $1,055,000 | $1,466,000 |
| Net Short Term Debt Issuance | $435,000 | $1,000,000 | $1,055,000 | $1,466,000 |
| Short Term Debt Issuance | $435,000 | $1,000,000 | $1,055,000 | $1,466,000 |
| Net Investment Purchase And Sale | $-3,000,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-14,000 | $0 | $0 | - |
| Purchase Of PPE | $-14,000 | $0 | $0 | - |
| Change In Working Capital | $-464,000 | $405,000 | $167,000 | $477,000 |
| Change In Other Working Capital | $12,000 | - | - | - |
| Change In Other Current Liabilities | $-27,000 | $0 | $0 | - |
| Change In Payables And Accrued Expense | $-79,000 | $317,000 | $155,000 | $303,000 |
| Change In Accrued Expense | $-231,000 | $322,000 | $271,000 | $153,000 |
| Change In Interest Payable | $-49,000 | $0 | $0 | - |
| Change In Payable | $152,000 | $-5,000 | $-116,000 | $150,000 |
| Change In Account Payable | $152,000 | $-5,000 | $-116,000 | $150,000 |
| Change In Prepaid Assets | $-370,000 | $88,000 | $12,000 | $174,000 |
| Stock Based Compensation | $447,000 | $10,000 | $39,000 | $23,000 |
| Gain Loss On Investment Securities | $952,000 | $443,000 | $-219,000 | $88,000 |
| Net Foreign Currency Exchange Gain Loss | $8,000 | $4,000 | $-13,000 | $10,000 |
| Net Income From Continuing Operations | $-5,805,000 | $-1,552,000 | $-1,005,000 | $-2,152,000 |
| Other Non Cash Items | - | $29,000 | $49,000 | $18,000 |
| Unrealized Gain Loss On Investment Securities | - | $443,000 | $-219,000 | $88,000 |
| Proceeds From Stock Option Exercised | - | - | $0 | $3,000 |
Fetched: 2026-06-19